GRFS
Grifols SA ADRNASDAQHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$6.65B
P/E Ratio
12.86
EPS
$0.63
Beta
1.21
52W High
$10.96
52W Low
$6.16
50-Day MA
$8.69
200-Day MA
$9.27
Dividend Yield
2.14%
Profit Margin
5.34%
Forward P/E
9.40
PEG Ratio
0.19
About Grifols SA ADR
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
Fundamentals
| Revenue (TTM) | $7.52B |
| Gross Profit (TTM) | $2.92B |
| EBITDA | $1.70B |
| Operating Margin | 17.50% |
| Return on Equity | 6.17% |
| Return on Assets | 4.24% |
| Revenue/Share (TTM) | $5.53 |
| Book Value | $8.96 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | 0.88 |
| EV/Revenue | 1.859 |
| EV/EBITDA | 8.57 |
| Quarterly Earnings Growth (YoY) | 43.50% |
| Quarterly Revenue Growth (YoY) | 0.30% |
| Shares Outstanding | $258.22M |
| Float | $417.31M |
| % Insiders | 0.00% |
| % Institutions | 57.31% |
Analyst Ratings
Consensus ($11.10 target)
1
Buy1
HoldData last updated: 4/8/2026